Table 1.

Demographic information and mean visual acuity at baseline and 6, 12, 18, 24 and 36 months (the number of eyes with a measurement at each point is shown in parentheses). Data on treatment burden and the numbers and percentages of eyes switching treatment are also shown

	Anti-VEGF	Macular laser	Dexamethasone
Mean age at baseline	72.0	72.5	71.9
Gender (% male)	47.4	48.6	45.9
Baseline CF (%)	57 (1.3)	14 (2.2)	14 (2.1)
Baseline HM (%)	23 (0.6)	2 (0.3)	3 (0.4)
Mean VA in ETDRS letters (n)
At baseline	57.1 (3859)	62.3 (620)	53.1 (659)
At 6 months	65.9 (1598)	60.9 (110)	59.7 (188)
At 12 months	66.7 (1042)	63.2 (53)	57.6 (95)
At 18 months	66.6 (713)	60.8 (48)	56.1 (71)
At24 months	67.2 (485)	56.4 (30)	59.3 (45)
At 36 months	68 (203)	50.1 (23)	62.9 (20)

	Anti-VEGF		Macular laser		Dexamethasone
	Visits	Treatments	Visits	Treatments	Visits	Treatments
Mean total visits and treatment visits (per patient)
At 6 months	5.2	3.8	2.3	1.1	3.9	1.3
At 12 months	7.9	5.1	3.2	1.2	5.6	1.5
At 18 months	9.5	5.9	3.8	1.2	6.6	1.7
At24 months	10.6	6.4	4.2	1.2	7.2	1.7
At 36 months	11.7	6.9	4.6	1.2	7.8	1.7
Treatment switching (%)
To anti-VEGF	-		80 (12.6)		285 (42.2)
To macular laser	267 (6.8)		-		63 (9.3)
To dexamethasone	162 (4.1)		83 (13.0)		-

anti-VEGF, anti-vascular endothelial growth factor; CF, counting fingers; HM, hand movement; VA, visual acuity.

anti-VEGF, anti-vascular endothelial growth factor.